PAVmed (PAVM) Q3 2026 earnings review
Medicare pays PAVmed's affiliate, but parent cash stays locked up
PAVmed's diagnostics affiliate finally won Medicare payments, but the parent holding company's own balance sheet grew tighter. Chief executive Lishan Aklog highlighted that Lucid Diagnostics began collecting Medicare claims for its esophageal test in October, driving monthly volume above 1,800 tests. However, at the PAVmed parent level, the net loss excluding one-offs nearly tripled from a year ago to $1.2 million as device research costs rose. While total cash reached $8.9 million, $5.3 million is locked up as restricted cash, leaving $3.6 million in usable funds by our math.
| Consolidated revenue | $41K $5K a year ago; $33K last quarter |
|---|---|
| Net loss, excluding one-offs | $1.24M $0.45M loss a year ago |
| Unrestricted cash (by our math) | $3.6M out of $8.9M total cash ($5.3M restricted) |
| Device regulatory timeline | Held Veris 510(k) early 2027; PortIO & Octeris Jan 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because commercial progress at Lucid is offset by tighter parent-level debt constraints. Winning Medicare payment removes the main commercial hurdle for Lucid, and Veris Health kept its early 2027 regulatory target on track by starting animal trials. The bad news: a $10 million markdown on PAVmed's Lucid shares pushed that stake's value down to about $23.5 million by our math, below the $30 million level required by PAVmed's senior debt.
The question now is whether Lucid's Medicare milestone rescues PAVmed's balance sheet before debt rules force another costly restructuring. Either Medicare collections lift Lucid's value back above covenant floors and unlock warrant cash, or the senior lender retains control over restricted funds while ongoing burn forces more share dilution. The debt footnotes in the upcoming third-quarter Form 10-Q filing will tell.
🐂 Bull Case
Medicare Starts Paying for Lucid's Esophageal Test
"Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone," chief executive Lishan Aklog said. EsoGuard is a DNA test for detecting precancer of the esophagus without an invasive scope, sold by PAVmed's affiliate Lucid Diagnostics. In October, Lucid began receiving Medicare payments at the established federal fee schedule rate from Novitas, the regional administrator covering its Texas laboratory.
Medicare beneficiaries represent about half of the 30 million U.S. patients recommended for screening. Before payments began, third-quarter volume stayed sluggish at 2,871 tests, bringing in $1.2 million of revenue for Lucid. Once coverage started in October, monthly volume jumped to a record of more than 1,800 tests, which is 88% above the third-quarter monthly average by our math.
What to watch: Lucid's fourth-quarter revenue collection rate on those Medicare claims. High collections will prove that regional coverage turns record test volume into actual cash without requiring a new national policy.
Device Pipeline Hits Design Freeze and Starts FDA Talks
PAVmed develops medical devices through its subsidiaries Veris Health, a remote cancer monitoring business, and Octeris Medical, an endoscopic imaging business, alongside its own PortIO vascular access device. This quarter, the medical technology group moved all three hardware programs into regulatory or preclinical testing phases.
- Veris implantable monitor: completed design freeze in the third quarter and started a 90-day animal study in October, "keeping the device on track for an early 2027 FDA 510(k) submission"
- PortIO vascular access device: held an initial Food and Drug Administration meeting in late October, ahead of its fourth-quarter request goal, with an in-person meeting set for January 2027 "focused on the device's regulatory pathway"
- Octeris imaging probe: completed its next-generation device, which is "ready for clinical testing" at the University of North Carolina starting in January 2027
What to watch: the outcome of January's in-person regulatory meeting for PortIO. Confirmation of a standard 510(k) clearance pathway would avoid a longer and costlier trial process.
🐻 Bear Case
Lucid Stake Markdown Pushes Value Below Debt Threshold
"As Lucid's largest common shareholder, PAVmed stands to benefit directly from Lucid's substantial near-term revenue opportunity," Aklog said. Because PAVmed deconsolidates Lucid, it carries those shares on its balance sheet as an equity-method investment marked to market each quarter. That stake also backs PAVmed's $15 million senior secured note, which requires the Lucid shares to be worth at least twice the note, or $30 million.
In the third quarter, PAVmed booked a $10.0 million non-cash loss from the drop in fair value of its equity-method investments. Subtracting that charge from June's $33.5 million balance leaves the Lucid stake at about $23.5 million by our math. That puts the holding below the $30 million threshold required since July, and close to the note's $20 million absolute floor.
What to watch: the debt footnote in the upcoming third-quarter Form 10-Q filing. A disclosed breach or costly lender waiver would show that Lucid's stock drop has impaired the parent company's solvency.
Restricted Cash Locks Up Most of the Balance Sheet
PAVmed reported $8.9 million in total cash and cash equivalents at the end of September, up from $3.8 million in June and $1.5 million in December 2025. However, the preliminary release reveals that $5.3 million of September's cash is restricted, compared with only $0.3 million in December.
By our math, that $5.0 million increase in restricted cash matches the blocked account deposit required by PAVmed's senior lender in August to keep a debt covenant amendment alive. Stripping out restricted funds leaves just $3.6 million in usable cash by our math, down from $3.8 million in June. Furthermore, the debt agreement required $8.0 million in minimum cash starting September 15, leaving unclear whether restricted cash counts toward that rule.
What to watch: the liquidity and debt footnotes in the third-quarter Form 10-Q filing. They will show where the $5.0 million came from and whether the lender waived the September cash requirement.
Parent Cash Burn and Share Dilution Keep Rising
PAVmed relies on Veris Health to build standalone revenue while its medical devices are in testing. Enrollment in the Veris cancer monitoring platform at Ohio State University grew throughout the quarter, "nearly doubling from July to September", the company said. Yet consolidated revenue reached only $41 thousand, up $8 thousand from the second quarter.
Meanwhile, operating expenses excluding one-offs rose 28.5% from a year ago to $5.6 million, driven by Veris research costs and general overhead. That pushed the net loss excluding one-offs to $1.2 million, nearly triple the $0.4 million loss a year ago. To fund operations, PAVmed keeps issuing equity, lifting its weighted average share count by 5.9% from last quarter and more than ninefold from a year ago to 6.6 million shares.
What to watch: fourth-quarter consolidated revenue and share count. If Ohio State enrollment does not lift quarterly revenue well above $41 thousand, parent operations will require further share dilution.
Risks this quarter didn't answer
Because PAVmed issued a preliminary earnings release without full financial statements or a conference call transcript, four standing financial and operational questions received no update.
- Series D warrant trigger: Lucid started receiving Medicare payments via Novitas, but the release does not say whether this satisfies the formal draft coverage policy required to call $30 million of warrants exercisable at $6.50 per share.
- Lucid management fee income: the release nets other income and expenses into a single $6.3 million charge, leaving the quarterly management services fee from Lucid undisclosed until the Form 10-Q filing.
- Ohio State patient count: management noted enrollment nearly doubled from July to September but gave no headcount toward its first-year goal of 1,000 patients.
- Biopharma licensing initiative: absent from company updates for a second straight quarter after earlier diligence promises.
💲 Other KPIs
The reported loss widened 85.7% from $6.3 million a year ago and more than doubled from $5.5 million in the second quarter. A $10.0 million non-cash accounting charge for the falling market value of PAVmed's stake in Lucid Diagnostics drove almost the entire increase.
Research spending excluding stock-based pay jumped 78.2% from $1.05 million a year ago as Veris Health completed its implantable monitor design and prepared animal trials. However, spending dipped 7.9% from $2.03 million in the second quarter as initial hardware design work wrapped up.
Revenue recognized by affiliate Lucid Diagnostics was unchanged from a year ago and fell 20.0% from $1.5 million in the second quarter on 2,871 processed tests. Because PAVmed accounts for Lucid as an equity investment, this figure sits outside PAVmed's $41 thousand consolidated sales.
🔮 Guidance
Unchanged. Management kept its target for an early 2027 regulatory submission after freezing the device design and starting a 90-day animal study in October. Across the prior six quarters, the company had pushed this target back four times from an original mid-2025 goal.
Accelerated. After planning to submit a meeting request in the fourth quarter, PAVmed held an initial Food and Drug Administration meeting in late October and scheduled an in-person session for January 2027 to set the clearance pathway.
New. With the next-generation imaging probe built, Octeris plans to file its initial Food and Drug Administration pre-submission package in November 2026 and begin enrolling patients at the University of North Carolina in January 2027.
❓ Key Questions
Where did the $5 million in restricted cash come from?
Total cash rose by $5.1 million from June while restricted cash reached $5.3 million. Investors need to know whether PAVmed borrowed more money or issued shares after June to fund the lender's $5 million blocked account.
Is the $15 million senior note currently in default?
By our math, the $10.0 million markdown drops PAVmed's Lucid stake to $23.5 million, below the $30 million debt rule, while unrestricted cash is $3.6 million against an $8.0 million September target. Management must clarify whether waivers are in place.
Do Novitas Medicare payments trigger the Series D warrants?
Lucid is getting paid by Medicare contractor Novitas, raising the question of whether this counts as the formal coverage policy needed to force exercise of $30 million in warrants, and whether holders would pay the $6.50 exercise price.
Why is Ohio State enrollment not lifting Veris revenue?
Monthly patient sign-ups at Ohio State nearly doubled between July and September, yet consolidated quarterly revenue rose by just $8 thousand to $41 thousand. Management has still not disclosed total enrolled patients or the price charged per patient.